{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "26939285", "DateCompleted": {"Year": "2016", "Month": "04", "Day": "08"}, "DateRevised": {"Year": "2016", "Month": "03", "Day": "04"}, "Article": {"ArticleDate": [], "ELocationID": [], "Language": ["eng"], "Journal": {"ISSN": "0071-786X", "JournalIssue": {"Volume": "71", "PubDate": {"Year": "2016"}}, "Title": "Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques", "ISOAbbreviation": "Prog Drug Res"}, "ArticleTitle": "Anti-tumour Activity.", "Pagination": {"StartPage": "165", "EndPage": "167", "MedlinePgn": "165-7"}, "Abstract": {"AbstractText": ["Experimental tumours have great importance for the purposes of modelling where Dalton's ascites lymphoma (DAL) and Ehrlich ascites carcinoma (EAC) are the commonest. It appeared firstly as a spontaneous breast cancer in a female mouse and then Ehrlich and Apolant (Berlin KlinWshr 28:871-874, 1905) used it as an experimental tumour by transplanting tumour tissues subcutaneously from mouse to mouse. In 1932, Loewenthal and Jahn obtained the liquid form in the peritoneum of the mouse and named it as 'Ehrlich ascites carcinoma' due to the ascites liquid, together with the carcinoma cells. In this chapter, two most common tumour cells (EAC and DAL) are chosen and protocol has been framed to determine the antitumor activity."]}, "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Prog Drug Res", "NlmUniqueID": "1304021", "ISSNLinking": "0071-786X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": ["methods"], "DescriptorName": "Bioprospecting"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Carcinoma, Ehrlich Tumor"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Discovery"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Phytochemicals"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug effects"], "DescriptorName": "Tumor Burden"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2016", "Month": "3", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "3", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "4", "Day": "9", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["26939285"]}}], "PubmedBookArticle": []}